Nexplanon 5-Year Approval Adds Mandatory REMS Training for Providers

The Nexplanon 5-year approval extends the etonogestrel implant from 3 to 5 years and requires every inserting clinician to complete REMS certification by August 23, 2026.

April 26, 2026 · 4 min read

The Story at a Glance:

The Nexplanon 5-year approval extends use of the etonogestrel implant from 3 years to 5 years (FDA, January 16, 2026)
The pivotal trial reported zero pregnancies during years 4 and 5 across BMIs from 17.2 to 64.3 kg/m²
A new Risk Evaluation and Mitigation Strategy (REMS) program took effect February 23, 2026, with provider certification due by August 23, 2026
Intermenstrual bleeding was the most common adverse reaction during extended use

What the Nexplanon 5-Year Approval Changes

The Nexplanon 5-year approval extends use of the etonogestrel implant for pregnancy prevention from 3 years to up to 5 years, the U.S. Food and Drug Administration (FDA) and Organon announced on January 16, 2026. The supplemental New Drug Application (sNDA) updates the label for the 68-mg radiopaque implant, a single subdermal rod that is one of the most effective long-acting reversible contraceptives (LARCs) available.

Alongside the duration change, FDA required a new Risk Evaluation and Mitigation Strategy (REMS) program to address complications from improper insertion and removal. The Nexplanon REMS officially launched on February 23, 2026, and every clinician who inserts or removes the implant must complete certification by August 23, 2026, or lose access to the product.

Approval was based on a multicenter, single-arm, open-label trial (NCT04626596) of 399 women aged 18 to 35 years already using the implant for 36 months, who continued treatment for 24 additional months. No pregnancies were reported during years 4 or 5.

Why the Nexplanon 5-Year Approval Matters

The Nexplanon 5-year approval ends a long-running gap between clinical guidance and the official label. For years, the World Health Organization and many U.S. clinicians had counseled extended use up to 5 years based on supportive evidence, but the 3-year label created uncertainty about insurance coverage, off-label liability, and patient confusion.

The updated label aligns prescribing with practice and means fewer office visits for replacement procedures over a patient’s reproductive years. The REMS, however, introduces a new administrative layer — every inserting clinician must enroll in the program, including those previously trained by Organon.

Key Numbers Behind the Nexplanon 5-Year Approval

The pivotal trial and REMS structure include several details OB/GYNs need to operationalize.

Trial design: Multicenter, single-arm, open-label; 399 women aged 18–35 years already using the implant for 36 months continued treatment for 24 additional months
Efficacy: Zero pregnancies during years 4 and 5
BMI range studied: 17.2 to 64.3 kg/m² (BMI = body mass index); 38.1% had a BMI ≥30 kg/m²
Safety: No new safety signals; intermenstrual bleeding was the most common adverse reaction
REMS deadline: Providers must enroll by August 23, 2026
Process for previously trained providers: Online knowledge assessment plus enrollment form, about 10 minutes
Process for new or lapsed providers: A 90-minute online didactic plus an in-person training before certification
Insertion technique: Unchanged; placement remains 3–5 cm posterior to the sulcus between the biceps and triceps

What Experts Are Saying

Anita Nelson, MD, professor of obstetrics and gynecology at Western University of Health Sciences, said the updated label aligns the prescribing language with the patient population now using the implant.

“reflects the diversity of patients we see every day” — Anita Nelson, MD, Professor of Obstetrics and Gynecology, Western University of Health Sciences

The Reproductive Health Access Project urged community clinicians not to wait until late summer, warning that providers who miss the August 23, 2026 deadline will be unable to order or place the implant until certification is complete — a meaningful access risk for clinics where the implant is a high-volume contraceptive option.

What’s Next for Nexplanon Providers

Existing patients with implants placed before the label update can leave them in for up to 5 years from the original insertion date. The REMS also requires clinicians to report potential insertion- and removal-related events (IRREs) to Organon through a dedicated reporting form or hotline.

Insurance coverage policies and clinical guidelines from ACOG and the Society of Family Planning will need updating to reflect the longer duration. Practices that rely on per-diem or rotating clinicians should track REMS certification status across staff to avoid disruptions in contraceptive access.

Bottom Line

Complete Nexplanon 5-year approval REMS certification well before the August 23, 2026 deadline (about 10 minutes for previously trained providers; longer for new clinicians)
Counsel patients with existing implants that their device is now indicated through 5 years from the original insertion date
Document insertion and removal events thoroughly and report any complications to the REMS as required
Reassure patients with overweight or obesity that the 5-year label applies across BMI categories studied up to 64.3 kg/m²

Sources

U.S. Food and Drug Administration. Nexplanon (etonogestrel) implant — Approval Letter, NDA 021529 supplement 027. January 16, 2026. FDA Approval Letter for Nexplanon sNDA 027
U.S. Food and Drug Administration. Nexplanon (etonogestrel) implant — Full Prescribing Information, 2026. Updated Nexplanon Prescribing Information (FDA, 2026)
Organon. Organon Announces US FDA Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON. Press release, January 16, 2026. Organon Announcement of Nexplanon 5-Year Approval
ClinicalTrials.gov. A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060). NCT04626596. ClinicalTrials.gov Record for Nexplanon Years 4–5 Trial
Reproductive Health Hotline. FDA Approves Updated Nexplanon Label and Launches New REMS: What to Know from ReproHH. December 29, 2025. ReproHH Clinician Briefing on Nexplanon REMS
Reproductive Health Access Project. Contraceptive Pearl: New FDA REMS Requirement on Nexplanon. March 2026. RHAP Contraceptive Pearl on Nexplanon REMS
Contemporary OB/GYN. FDA approves 5-year use for etonogestrel implant 68 mg contraceptive. January 2026. Contemporary OB/GYN Coverage of FDA Approval